Toggle Summary May 11, 2010
PRO-PHARMACEUTICALS CLOSES FINAL $570,000 TRANCHE FROM 10X FUND TO COMPLETE $6 MILLION RAISE
View HTML
Toggle Summary May 12, 2010
PRO-PHARMACEUTICALS REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS
View HTML
Toggle Summary May 24, 2010
PRO-PHARMACEUTICALS PREPARES PHASE III DAVANAT® TRIAL FOR SECOND HALF 2010
Peter G. Traber, M.D. Joins Trial Design Team to Finalize and Implement Strategy for FDA Approval
View HTML
Toggle Summary Jun 15, 2010
FORMER GLAXO SMITH KLINE CHIEF MEDICAL OFFICER PETER G. TRABER, M.D., NAMED CHIEF MEDICAL OFFICER OF PRO-PHARMACEUTICALS
Dr. Traber Will Lead Design of Phase lll Colorectal Cancer Trial for DAVANAT® and the Company's FDA Approval Strategy
View HTML
Toggle Summary Jun 22, 2010
PRO-PHARMACEUTICALS RECEIVES FIRST COMMERCIAL ORDER FOR DAVANAT®
PROCAPS S.A. To Make Upfront Payment and Will Be Responsible for the Approval, Distribution, Marketing and Sales of DAVANAT® in Colombia
View HTML
Toggle Summary Aug 13, 2010
PRO-PHARMACEUTICALS REPORTS SECOND QUARTER 2010 AND SIX MONTHS FINANCIAL RESULTS
View HTML
Toggle Summary Aug 24, 2010
PRO-PHARMACEUTICALS' EXECUTIVES TO PRESENT CORPORATE UPDATE AT THREE INVESTOR CONFERENCES IN SEPTEMBER
Rodman and Renshaw Annual Global Investment Conference; BioPharm America 2010 MassBio Investors Forum, and Accredited Members Fall 2010 Small/Micro Cap Conference
View HTML
Toggle Summary Sep 10, 2010
PRO-PHARMACEUTICALS' PRESENTATION AT RODMAN AND RENSHAW'S ANNUAL GLOBAL INVESTMENT CONFERENCE TO BE WEBCAST LIVE
View HTML
Toggle Summary Sep 13, 2010
PRO-PHARMACEUTICALS COLLABORATES WITH NUMODA TO MANAGE PHASE lll CLINICAL TRIAL TO INCREASE SPEED-TO-MARKET FOR DAVANAT®
View HTML
Toggle Summary Oct 28, 2010
PRO-PHARMACEUTICALS SHIPS FIRST COMMERCIAL ORDER FOR DAVANAT®
South American Distributor PROCAPS S.A. To Market and Sell DAVANAT® in Colombia, South America
View HTML